文献速递肝病

预测肝硬化患者隐匿性肝性脑病预后评分的开发与验证

Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

该研究前瞻性纳入142例开发队列和96例验证队列的连续肝硬化患者,开发并验证了包含临床可检测腹水、显性肝性脑病(OHE)史、血清白蛋白水平、慢性肝病问卷活动子域和简化动物命名试验的临床隐匿性肝性脑病(CHE)评分。该评分以两个截断值区分高、中、低风险组,开发队列AUC为0.908,验证队列AUC为0.872,高风险组可预测180天内首次OHE。

要点

  • 临床CHE评分包含腹水、OHE史、白蛋白、慢性肝病问卷活动子域和简化动物命名试验。
  • 两个截断值将患者分为高、中、低风险组,中风险组需额外专门测试。
  • 应用截断值后灵敏度90%、特异度91%、阳性预测值85%、阴性预测值94%。

核心结论

  • 开发了一种易于执行的评分来识别有CHE风险的肝硬化患者,该评分与生活质量和首次OHE风险相关。

研究设计与样本

  • 前瞻性纳入142例开发队列和96例验证队列的连续肝硬化患者,采用心理测量肝性脑病评分检测轻微肝性脑病,所有患者接受简化动物命名试验并完成慢性肝病问卷,遵循TRIPOD指南进行开发、验证和报告。

主要发现

  • 临床CHE评分包含临床可检测腹水、OHE史、血清白蛋白水平、慢性肝病问卷活动子域和简化动物命名试验,能最好地区分有无CHE的患者。
  • 应用两个截断值后,灵敏度、特异度、阳性预测值和阴性预测值分别为90%、91%、85%和94%。
  • 开发队列AUC为0.908,验证队列AUC为0.872。
  • 评分越高与生活质量越差相关,高风险组可预测180天内首次OHE。

关键数值与推荐

  • 临床CHE评分包含变量:临床可检测腹水、OHE史、血清白蛋白水平、慢性肝病问卷活动子域、简化动物命名试验。
  • 生成两个截断值用于识别高、中(需额外专门测试)、低风险组。
  • 应用截断值后灵敏度90%、特异度91%、阳性预测值85%、阴性预测值94%。
  • 开发队列AUC为0.908,验证队列AUC为0.872。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Diagnosis of covert hepatic encephalopathy (CHE) is challenging and often neglected in clinical practice. The aim of this study was to develop an easy-to-perform score to predict CHE in patients with cirrhosis. METHODS: For the development or validation cohort of the proposed clinical CHE score, 142 or 96 consecutive patients with cirrhosis were prospectively enrolled. The Psychometric Hepatic Encephalopathy Score was used to detect minimal hepatic encephalopathy. All patients were examined with the simplified animal naming test and were asked to complete the Chronic Liver Disease Questionnaire. We followed the TRIPOD guideline for development, validation, and reporting of the proposed score. RESULTS: The clinical covert hepatic encephalopathy score containing the variables-clinically detectable ascites, history of overt hepatic encephalopathy (OHE), albumin serum level, activity subdomain of the Chronic Liver Disease Questionnaire, and simplified animal naming test-discriminated best between patients with and without CHE. We generated 2 cutoff values for the identification of the high-, intermediate- (with need for additional specialized testing), and low-risk groups for CHE. By applying these cutoffs, the sensitivity, specificity, positive predictive value, and negative predictive value were 90%, 91%, 85%, and 94%, respectively. The AUC was 0.908 or 0.872 for the development or the validation cohort, respectively. Higher scores were further associated with poorer quality of life, and the high-risk group was predictive for first-time OHE within 180 days. CONCLUSIONS: We developed an easy-to-perform score to identify patients with cirrhosis at risk of CHE, which correlates with quality of life and risk of first-time OHE.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Labenz C, Toenges G, Huber Y, et al. Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. Am J Gastroenterol. 2019. PMID: 30848730. doi:10.14309/ajg.0000000000000121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。